Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Ultrasonic Fluid Processor

By Drug Discovery Trends Editor | April 15, 2010

At the Society for Biomecular Sciences (SBS) 16th Annual Conference & Exhibition in Phoenix, Microsonic Systems Inc. (“Microsonics”) announced that its HENDRIX SM100 Ultrasonic Fluid Processor (“HENDRIX SM100”) significantly improves fragment-based drug screening quality by re-solubilizing precipitated samples back into solution.

Recent data shows that by adding the HENDRIX SM100 to the fragment-based drug discovery process, researchers are able to re-solubilize precipitated fragment libraries and consequently “recover” the originally “lost” samples. This process both increases the sample concentrations and improves the accuracy of screening results.

“Using Lateral Ultrasonic Thrust™ technology to solubilize, thaw, mix and suspend is proving to be a highly effective tool to increase screening yields,” stated Bruce Jamieson, Senior Vice President of Sales & Marketing. “In fact, our customers have told us that by virtually eliminating precipitates from their compound libraries, the HENDRIX SM100 is allowing them to screen a significantly higher proportion of their compounds than they would have been able to otherwise, a process we are calling ‘secondary recovery.’”

Microsonics will be presenting a poster at the SBS conference titled “Improve the Integrity of Your Fragment Library for Fragment-Based Drug Discovery”. The poster reports experimental data that shows that, compared to the control group, the secondary recovery process increases primary screening activity by up to 384%, and by as much as two logs of concentration reduction in fragment IC50 values.

Fragment-based drug discovery (FBDD) is gaining recognition for its many advantages over high-throughput screening, including better hit-to-lead rates and broad chemical space for possible compound scaffolds. Due to the low affinity of fragments for biological targets, fragment libraries may contain weak hits, requiring screening concentrations as high as 200mM. Although many fragments are soluble  in DMSO, environmental shocks introduced by DMSO hydration or repeat freeze/thaw cycles can cause precipitation, and consequently affect the accuracy of FBDD screening results. Using the HENDRIX SM100, precipitates can now be recovered across an entire microplate or tube rack simultaneously in just a few minutes.

Date: April 13, 2010
Source: Microsonic Systems 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE